|
|
News Breaks | | | | July 11, 2012 | | 08:06 EDT |  | PATH | NuPathe announces allowance of additional U.S. Patent application for NP202
NuPathe announced that the U.S. Patent and Trademark Office, or USPTO, has issued a Notice of Allowance for U.S. Patent Application 11/195,845 titled "Drug Containing Implants and Methods of Use Thereof." The allowed claims relate to a rod-shaped implant or structure that delivers therapeutic levels of risperidone for 20 to 190 days as well as to methods for treating medication noncompliance-associated diseases including schizophrenia and bipolar disorder. Given this action, NuPathe expects the patent to issue within the next few months. Once issued, it will provide patent protection through December 2027 for NP202, NuPathe's long-term biodegradable risperidone implant for the treatment of schizophrenia and bipolar disorder. NuPathe has a portfolio of additional licensed patent applications pending in the U.S. and other territories for NP202. | |
|
News For PATH From The Last 14 Days Check below for free stories on PATH the last two weeks. |
|
|
| May 14, 2013 | | 07:38 EDT |  | PATH | NuPathe reports Q1 EPS (68c) with items, consensus (17c)
 Subscribe for More Information | | | May 13, 2013 | | 15:27 EDT | | PATH | Notable companies reporting after market close
Notable companies reporting before tomorrow's open, with earnings consensus, include AutoNavi Holdings (AMAP), consensus 19c; Hi-Crush Partners (HCLP), consensus 50c; Global Sources (GSOL), one estimate 17c; General Finance (GFN), one estimate 11c; NuPathe (PATH), consensus (17c). | | | 08:22 EDT | | PATH | NuPathe announces allowance of U.S. patent application for NP201
Subscribe for More Information | |
|
|
|
|
|
|
